Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.32 |
| ▸ | PER2 | O15055 | 2/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109684 | 0.78 | AR (0.37) | ARPDE3BPDE3A | |
| SCHEMBL24109681 | 0.78 | PDE3B (0.30) | PDE3BPDE3A | |
| SCHEMBL24109994 | 0.73 | — | — | |
| SCHEMBL24109998 | 0.73 | SMO (0.35) | AR | |
| SCHEMBL16639240 | 0.60 | CA1 (0.37) | PER2CRY2CA1CA2CA7 | |
| SCHEMBL31277781 | 0.59 | AKR1B1 (0.40) | CA1CA2CA7CA9 | |
| SCHEMBL3700761 | 0.59 | AKR1B1 (0.40) | CA1CA2CA7CA9 | |
| SCHEMBL18002676 | 0.58 | AR (0.42) | ARP2RX7TRPA1PDE3BPDE3A | |
| SCHEMBL28570266 | 0.57 | AR (0.47) | ARTRPA1PDE3BPDE3A | |
| SCHEMBL4718971 | 0.56 | CHRM5 (0.33) | ARPER2TRPA1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2023-07-13 | — | — | US | claimed |
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | CYP11B2, CYP11B1, CYP1B1 | AR 1068/4885PER2 4105/4885CRY2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.